Compare SMID & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | HUMA |
|---|---|---|
| Founded | 1960 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.8M | 182.6M |
| IPO Year | 1995 | N/A |
| Metric | SMID | HUMA |
|---|---|---|
| Price | $35.80 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 5.4K | ★ 4.2M |
| Earning Date | 11-13-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $88,866,000.00 | $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $731.05 |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $25.13 | $0.88 |
| 52 Week High | $43.66 | $4.45 |
| Indicator | SMID | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.32 |
| Support Level | N/A | $0.88 |
| Resistance Level | N/A | $1.03 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 11.15 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.